Multipotent Stem Cells in Post Natal Bone Marrow
Multipotent Stem Cells in Post Natal Bone Marrow
批准号:
6621863
负责人:
CATHERINE M VERFAILLIE
金额:
$30.44万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-03-01 至 2006-12-31
关键词:
autocrine bone marrow cell differentiation cell proliferation cell sorting cell type embryonic stem cell gene expression genetic promoter element genetically modified animals genotype green fluorescent proteins laboratory mouse mature animal mesenchyme mesoderm monoclonal antibody newborn animals phenotype stem cell transplantation tissue /cell culture
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): A stem cell is a cell with extensive
proliferation potential that can differentiate into several cell types. The
quintessential stem cell is the embryonal stem (ES) cell which has unlimited
self renewal and multipotent differentiation potential. Tissue specific stem
cells have less self-renewal ability and are not multipotent. A number of
recent studies suggest that tissue specific stem cells may have the ability to
generate cells of tissues from unrelated organs. Whether this unexpected
plasticity constitutes "transdifferentiation" or whether a small population of
multipotent stem cells persists in post-natal tissues is not known The finding
that stem cells exist in post-natal tissues with previously unknown
proliferation and differentiation potential opens up the possibility of using
autologous stem cells to treat a host of degenerative, traumatic or congenital
diseases. Aside from the immunological advantage of using autologous stem
cells, tissue derived stem cells are also not encumbered by ethical
considerations. We identified cells in human (h), murine (m) and rat (r),
post-natal bone marrow (BM) that have, at the single cell level, multipotent
differentiation and extensive proliferation potential. which we named
Multipotent Adult Progenitor Cell or MAPC. (A) hMAPC, mMAPC and rMAPC
differentiate in vitro mesodermal cell types, cells with neuroectodermal and
with endodermal features. (B) Using retroviral marking and evaluation of the
integrant insertion site, we have shown for hMAPC that multi-lineage
differentiation is derived from single cells. (C) hMAPC, mMAPC and rMA.PC
express active telomerase and can undergo 90+ cell doublings without telomere
shortening, suggesting that they do not senesce. (D) hMAPC. mMAPC and rMAPC
express oct-4, Rex-i mRNA and a fraction of cultured hMAPC stain with the Ab,
SSEA-4. (E) We have evidence that MAPC engraft in vivo and persist for 2+
months even though single cell origin of the engrafted cells that differentiate
in multiple tissue specific cells has not yet been proven. (F) Similar cells
with extensive proliferative and multilineage differentiation potential can be
found in murine brain and muscle. Because MAPC containing cultures are still
heterogeneous, we plan to further characterize the phenotype and genotype of
MAPC. We will also test the hypothesis that MAPC may exist in other organs but
that the phenotype of MAPC derived from different organs will be similar. This
will be accomplished in the following 3 aims: SA1: To define the cell-surface
phenotypic characteristics and expressed gene profile of MAPC. As has been
shown for other stem cells, we believe that MAPC can be selected from fresh
tissue to high purity based on cell surface or functional (e.g. quiescence)
characteristics. The expressed gene profile of MAPC will allow us to
discriminate between MAPC and tissue committed stem cells, such as MSC. We also
have preliminary evidence that MAPC may exist in tissues other than BM and plan
to further characterize MAPC from other organs in mouse. SA2: To further define
the growth requirements of MAPC. We will test if autocrine factors are
necessary for optimal MAPC growth in vitro, and whether presence of more
committed progenitors negatively impacts on culture of MAPC to homogeneity.
SA3: To define the in vivo differentiation capacity of mMAPC. Final proof that
MAPC are true stem cells will require that we demonstrate long-term engraftment
and differentiation into mesodermal and non-mesodermal cell types at the clonal
level in vivo. We will test whether MAPC differentiate in vivo to tissue
specific cells and whether this is enhanced when organs are damaged.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Scientific Meeting
-
批准号:7251414
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2006
-
负责人:CATHERINE M VERFAILLIE
-
依托单位:
BONE MARROW ASPIRATE FOR HEMATOPOIETIC AND MESENCHYMAL STEM CELLS
-
批准号:7206484
-
项目类别:
-
资助金额:$0.59万
-
财政年份:2005
-
负责人:CATHERINE M VERFAILLIE
-
依托单位:
BONE MARROW ASPIRATE FOR HEMATOPOIETIC AND MESENCHYMAL STEM CELLS
-
批准号:7375897
-
项目类别:
-
资助金额:$0.43万
-
财政年份:2005
-
负责人:CATHERINE M VERFAILLIE
-
依托单位:
Stem Cells
-
批准号:7192029
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2005
-
负责人:CATHERINE M VERFAILLIE
-
依托单位:
Genetic Control of Hematopoietic Development
-
批准号:6983708
-
项目类别:
-
资助金额:$22.33万
-
财政年份:2005
-
负责人:CATHERINE M VERFAILLIE
-
依托单位:
Stem Cells
-
批准号:7058440
-
项目类别:
-
资助金额:$1.2万
-
财政年份:2005
-
负责人:CATHERINE M VERFAILLIE
-
依托单位:
MInnesota Human MAPC Training Grant
-
批准号:6881561
-
项目类别:
-
资助金额:$12.35万
-
财政年份:2004
-
负责人:CATHERINE M VERFAILLIE
-
依托单位:
MInnesota Human MAPC Training Grant
-
批准号:7052068
-
项目类别:
-
资助金额:$12.71万
-
财政年份:2004
-
负责人:CATHERINE M VERFAILLIE
-
依托单位:
MInnesota Human MAPC Training Grant
-
批准号:6770707
-
项目类别:
-
资助金额:$12.0万
-
财政年份:2004
-
负责人:CATHERINE M VERFAILLIE
-
依托单位:
Mesenchymal Stem Cell Therapy: a1 antitrypsin deficiency
-
批准号:6602918
-
项目类别:
-
资助金额:$36.4万
-
财政年份:2003
-
负责人:CATHERINE M VERFAILLIE
-
依托单位:
Bone Marrow Aspirate for Hematopoietic and Mesenchymal Stem Cells
-
批准号:7041995
-
项目类别:
-
资助金额:$0.81万
-
财政年份:2003
-
负责人:CATHERINE M VERFAILLIE
-
依托单位:
Mesenchymal Stem Cell Therapy a1 antitrypsin deficiency
-
批准号:6728207
-
项目类别:
-
资助金额:$35.36万
-
财政年份:2003
-
负责人:CATHERINE M VERFAILLIE
-
依托单位:
Mesenchymal Stem Cell Therapy a1 antitrypsin deficiency
-
批准号:6876051
-
项目类别:
-
资助金额:$35.19万
-
财政年份:2003
-
负责人:CATHERINE M VERFAILLIE
-
依托单位:
Mesenchymal Stem Cell Therapy a1 antitrypsin deficiency
-
批准号:7046018
-
项目类别:
-
资助金额:$34.3万
-
财政年份:2003
-
负责人:CATHERINE M VERFAILLIE
-
依托单位:
FACS Vantage SE
-
批准号:6581487
-
项目类别:
-
资助金额:$47.15万
-
财政年份:2003
-
负责人:CATHERINE M VERFAILLIE
-
依托单位:
Multipotent Stem Cells in Post Natal Bone Marrow
-
批准号:6704757
-
项目类别:
-
资助金额:$30.44万
-
财政年份:2002
-
负责人:CATHERINE M VERFAILLIE
-
依托单位:
Multipotent Stem Cells in Post Natal Bone Marrow
-
批准号:6437097
-
项目类别:
-
资助金额:$29.05万
-
财政年份:2002
-
负责人:CATHERINE M VERFAILLIE
-
依托单位:
Multipotent Stem Cells in Post Natal Bone Marrow
-
批准号:6986188
-
项目类别:
-
资助金额:$29.73万
-
财政年份:2002
-
负责人:CATHERINE M VERFAILLIE
-
依托单位:
Multipotent Stem Cells in Post Natal Bone Marrow
-
批准号:6836571
-
项目类别:
-
资助金额:$30.44万
-
财政年份:2002
-
负责人:CATHERINE M VERFAILLIE
-
依托单位:
Stem Cell Therapy for Hemophilia A
-
批准号:6361651
-
项目类别:
-
资助金额:$28.2万
-
财政年份:2001
-
负责人:CATHERINE M VERFAILLIE
-
依托单位:
海外基金